#USA #Lund #TFS HealthScience #Katarina Ageborg #Markus Granlund

TFS HealthScience Leadership Transition

TFS HealthScience, a leading global Contract Research Organization (CRO), has recently announced a significant leadership transition. Effective immediately, Katarina Ageborg has been appointed as the Chair of the Board, while Markus Granlund steps in as the Acting CEO. These leadership changes signal a fresh and exciting chapter for TFS as the organization aims to further its mission of enhancing health and wellness treatments worldwide.

New Leadership Contributions

Katarina Ageborg is an industry veteran with over 25 years of executive experience, including senior roles at AstraZeneca, where she was part of the global executive team. Her background in strategic leadership, corporate governance, and patient-centered innovation is expected to play a pivotal role in defining TFS’s future direction. As Chair of the Board, Ageborg will focus on strengthening TFS’s global position, deepening customer relationships, and driving ongoing growth.

Moreover, Markus Granlund brings extensive experience in international operations management to TFS. Since joining the Board in October 2024, he has demonstrated his capabilities in leading global teams and achieving operational excellence. Granlund, who previously spent 16 years at Semcon, transitioning from his role as CEO, sees this new role as a platform to continue advancing TFS's services.

Granlund expressed his enthusiasm about contributing to TFS’s growth landscape, stating, “I am excited to work alongside our talented teams as we continue to strengthen TFS’s position in the industry. With a focus on agility, operational excellence, and deep partnerships, we will evolve to meet our clients' needs and provide solutions that truly impact patients’ lives globally.”

Commitment to Clients and Innovation

Under the guidance of Ageborg and Granlund, TFS is poised to enhance its scientific expertise and operational excellence. Furthermore, the CRO aims to broaden its capabilities across key therapeutic areas, ensuring that the organization can deliver high-quality, flexible solutions. This dedication to innovation and strategic partnerships underscores TFS’s commitment to providing valuable clinical research services for biotechnology and pharmaceutical companies worldwide.

Granlund further explained, “This leadership transition aims to build on our momentum and ensure TFS remains a trusted partner for biopharmaceutical companies across the globe. We are committed to delivering high-quality clinical research services while prioritizing innovation and always putting patients at the center of what we do.”

About TFS HealthScience

TFS HealthScience is a global full-service Contract Research Organization (CRO) that collaborates with biotech and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With nearly 700 professionals across 40 countries, TFS and its strategic partners offer bespoke strategic resource solutions and clinical development services in specialized therapeutic areas. The company is dedicated to empowering partners and enriching lives, providing flexible solutions that combine global reach with the agility and responsiveness characteristic of a mid-sized CRO. For more information, visit www.tfscro.com.